NCT01582191View on ClinicalTrials.gov

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

May 14, 2012

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Advanced Malignant NeoplasmMetastatic Malignant NeoplasmRecurrent Malignant NeoplasmRefractory Malignant Neoplasm
Interventions
DRUG

Everolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

OTHER

Pharmacological Study

Optional correlative studies

DRUG

Vandetanib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER